Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

9.405 -0.155 (-1.62%)
Streaming Delayed Price Updated: 1:30 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research 
Via Benzinga
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
A Glimpse of Intellia Therapeutics's Earnings Potential
Via Benzinga
Assessing Intellia Therapeutics: Insights From 9 Financial Analysts
Via Benzinga
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration
Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds. 
Via Benzinga
Topics Government
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Keep an eye on the top gainers and losers in Thursday's session.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip
The patient’s elevated levels of liver enzymes appear to be resolving without hospitalization or medical intervention, the company said. 
Via Stocktwits
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course
Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment remains on track across programs. 
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
HP Posts Downbeat Earnings, Joins SentinelOne, Best Buy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
What's going on in today's pre-market session
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Analysts Think These Stocks Could More Than Double in Value
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well. 
Via MarketBeat
Topics World Trade
INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Forecasting The Future: 11 Analyst Projections For Intellia Therapeutics
Via Benzinga
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite stocks. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms
ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details. 
Via Benzinga
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Via Benzinga
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
NTLA Investors Have the Opportunity to Lead the Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.